Is retroviral gene marking too dangerous to use?

Cytotherapy

Volumn 5, Issue 3, 2003, Pages 190-193

  Brenner, Malcolm K ^a   Heslop, H E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CD40 LIGAND; GENE PRODUCT; GROWTH FACTOR; KANAMYCIN KINASE; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW; CANCER; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; DENDRITIC CELL; DNA SEQUENCE; GENE TRANSFER; GENETIC CODE; GENETIC MARKER; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; INFECTION; LEUKEMIA; LYMPHOMA; NEUROBLASTOMA; NONHUMAN; NOTE; PROGENY; RETROVIRUS; RISK; SOLID TUMOR; SUICIDE GENE THERAPY; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; TREATMENT FAILURE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; VIRAL GENE THERAPY;

EID: 0042194477     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240310001307     Document Type: Article

References (26)

1. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-6.
2. Orkin SH, Motulsky AG. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. http://www4.od.nih.gov/oba/rac/panelrep.htm visited 13th May 2003.
3. Brenner MK, Rill DR, Holladay MS et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993;342:1134-7.
4. Rosenberg SA, Blaese RM, Anderson WF. The N2-TIL human gene transfer clinical protocol. Hum Gene Ther 1990;1:73-92.
5. Rosenberg SA, Aebersold P, Cornetta K et al. Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-8.
6. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993;341:85-6.
7. Deisseroth AB, Kantarjian H, Talpaz M et al. Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: A pilot trial. Hum Gene Ther 1991;2:359-76.
8. Dunbar CE, Cottler-Fox M, O'Shaunessy JA et al. Retrovirally marked CD34-enriched peripheral blood and marrow cells contribute to long term engraftment after autologous transplantation. Blood 1995;85:3047-57.
9. Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-5.
10. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998;92:1073-90.
11. To LB, Haylock D, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997;89:2233-58.
12. Nieto Y, Shpall EJ. Autologous stem-cell transplantation for solid tumors in adults. Hematol Oncol Clin North Am 1999;13:939-68.
13. Johnston LJ, Horning SJ. Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1999;13:889-918.
14. Bensinger WI. Should we purge? [editorial; comment]. Bone Marrow Transplant 1998;21:113-5.
15. Zwicky CS, Maddocks AB, Andersen N, Gribben JG. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangements in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996;88:3314-22.
16. Brenner M, Mirro J Jr, Hurwitz C et al. Autologous bone marrow transplant for children with AML in first complete remission: Use of marker genes to investigate the bioloby of marrow reconstitution and the mechanism of relapse. Hum Gene Ther 1991;2:137.
17. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-3.
18. Cornetta K, Srour EF, Moore A et al. Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. Hum Gene Ther 1996;7:1323-9.
19. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1998;83:3068-76.
20. Santana VM, Brenner MK, Ihle J et al. A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: Use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse. Hum Gene Ther 1991;3:257-72.
21. Cornetta K, Tricot G, Broun ER et al. Retroviral-mediated gene transfer of bone marrow cells during autologous bone marrow transplantation for acute leukemia. Hum Gene Ther 1992;3:305-18.
22. Rooney CM, Smith CA, Ng C et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995;345:9-13.
23. Roskrow MA, Suzuki N, Gan Y-J et al. EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease. Blood 1998;91:2925-34.
24. Brodie SJ, Lewinsohn DA, Patterson BK et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells [comments]. Nat Med 1999;5:34-41.
25. Rooney CM, Smith CA, Ng CYC et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-55.
26. Brown MP, Topham DJ, Sangster MY et al. Thymic lymphoproliferative disease after successful correction of CD 40 ligand deficiency by gene transfer in mice. Nat Med 1998;4:1253-60.